GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Barinthus Biotherapeutics has shared its most significant recent data from the ongoing Phase IIb HBV003 clinical trial for chronic hepatitis B. The newest data was cut off on 30 September (for lab ...

"GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Twenty-seven patients with Chronic Hepatitis B Virus infection (CHB ... intramuscular (i.m.) injection VRON-0200 is a Phase 1b, multi-center, open-label, dose escalation, prime only, and prime ...

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains ... are asymptomatic during the early and chronic stages of infection even as the virus, one of the smallest ...

Trials with Heplisav were halted last month in response to a serious adverse effect report from a phase 3 trial comparing Heplisav to a marketed hepatitis B vaccine, Engerix-B, sold by ...

Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...